Knowledge HQ

CAR-T cell therapy has emerged as a powerful weapon in the fight against specific B-cell malignancies. Its success has fueled significant research efforts to broaden its reach to encompass a wider range of hematologic and solid tumors.    Optimizing CAR-T cell therapy hinges on a deeper understanding of the intricate signaling pathways that govern these potent immune cells. This includes their ability to infiltrate tumors, evade antigen escape mechanisms, resist immunosuppression, and minimize potentially fatal toxicities. To achieve this, researchers require a comprehensive characterization of the signaling molecules involved, encompassing the extracellular, membrane-bound, and intracellular compartments. However, this endeavor is often hampered by limited and complex sample types.    The Wilson Wolf G-Rex platform offers a unique solution for large-scale expansion of CAR-T cells, enabling researchers to study these vital communication networks within larger, more robust cell populations. This facilitates a deeper understanding of CAR-T cell function and paves the way for the development of safer and more effective CAR-T therapies.    Unleash the Full Potential of CAR-T Cells: Learn More  Understanding these vital communication networks within CAR-T cells is critical to unlocking their full potential. Download our free App Note: Analytical Tools to Evaluate CAR-T Cell Signaling & Activation to explore the latest advancements in research methods for optimizing CAR-T cell therapy. 

Current methods of final formulation fill and finish either require manual processing which has the potential to result in operator error, or utilized automated systems with limited capabilities. Manual methods or semi-automated systems may present the risk of increased exposure time of cells to DMSO within the cryoprotectant, causing a reduction in post-thaw viability and recovery. The Cue Cell Processing System is a functionally closed and fully automated instrument with enhanced system functionalities for F/F/F of Cell and Gene therapy products

The case study illustrates ScaleReady's effective use of technology and tailored strategies to overcome AgonOx's challenges. Through detailed analysis and strategic implementation of ScaleReady technology, analytics, and automation, ScaleReady achieved significant improvements in customer satisfaction and operational efficiency.  

TcBuster-MTM (TcB-MTM) is a commercially available non-viral transposase-based editing platform that overcomes current viral limitations. TcBuster is found in the red flour beetle and is a member of the hAT family of transposases. Using directed evolution, we engineered a hyperactive mutant (TcB-M) that has improved transposition rates using less mRNA transposase and NanoplasmidTM DNA transposon.

Current iNK differentiation protocols typically utilize xenogenic feeder cells, which could be problematic for patient safety, or they lack robustness and are highly variable in differentiation efficiency. Using animal-free small molecules and recombinant proteins, Bio-Techne developed a feeder-free differentiation process to reliably generate iNKs at scale by optimizing for CD34+ hematopoietic stem cells (iHSC) prior to downstream NK differentiation.

Aliquot accuracy whitepaper provides an in-depth look at how the Cue® Cell Processing System ensures consistency and quality in cell therapy products.

Download the ExCellerate NK Media Feeder-Cell G-Rex Culture Process

Download the protocol to support a feeder-free process in G-Rex cell culture.

ExCellerate NK Media offers a robust and versatile solution for NK cell cultures, designed to transition from research to clinical application seamlessly.

Utilization of G-Rex by introducing a new scalable depletion method: Coculturing target CAR T cells with an NK-92 cell line in G-Rex to purify their CAR T cells and promote CAR T cell expansion at the same time.